Sign up
Pharma Capital

SkinBioTherapeutics boss praises “significant progress” made with moisturising cream this year

The cream is currently undergoing its first-in-human studies, with researchers assessing its skin irritancy, moisturisation potential and skin barrier function
skin cream
Several consumer goods and cosmetics companies have shown an interest in the technology

SkinBioTherapeutics PLC (LON:SBTX) has made “significant progress” so far this year with the development of its moisturising cream, according to the life sciences group's chief executive, Cath O'Neill.

SkinBio kicked off the first-in-human studies of the technology last month, with researchers assessing skin irritancy, moisturisation potential and skin barrier function of different concentrations of the cream.

WATCH: SkinBioTherapeutics achieves 'commercial levels of scale-up' of its technology

The skin barrier study is the most ambitious of the three. It will attempt to ascertain whether the positive impact of the technology on the skin's barrier function seen in the lab is replicated in 120 female volunteers with dry skin.

Results from the first two trials – irritancy and moisturisation – are due in the coming weeks, although data from the skin barrier study won’t be ready until the first quarter of 2019.

Even though the technology is still in the development stage, SkinBio has already signed a material transfer agreement (MTA) with a global consumer goods company, while a “range” of other firms have taken a keen interest in the cream.

That is important, given that the long-term plan is to license out the technology to other companies for them to use in their lotions and potions.

Studies a ‘major milestone’

“This year, our focus has been on preparing the SkinBiotix technology for its first human study and longer-term preparations for commercialisation. On both fronts, we have made good progress,” said CEO O’Neill.

“Firstly, we have demonstrated that our lysate can be freeze-dried and scaled-up to industrial levels.

READ: First-in-human trial of SkinBio’s cream underway

“On the commercial front, we have an ongoing dialogue, including an MTA, with a range of major fast-moving consumer goods and cosmetic companies who are taking a close interest in our technology and progress.”

She added: “Post year end, we initiated the cosmetic human studies which were a major milestone for the Company. On the basis that the results are positive, the validation will strengthen our position as a science-led business and enable further commercial discussions.”

Cash in the bank

SkinBio made a loss before tax of £941,000 in the 12 months ended June 30, finishing the year with £3.2mln of cash in the bank (2017: £3.9mln).

Shares rose 2% to 19.1p in early deals on Thursday.

View full SBTX profile View Profile
View All

Related Articles

lung x-ray
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.